RET and hepatocellular carcinoma: For example, sorafenib, which was first approved for the treatment of advanced HCC, can act on receptors such as VEGFR1-3, PDGFR-β, C-kit, RET, and PLT3, and extending the survival of patients with advanced HCC by blocking the information transmission of tumor cells, inhibiting tumor angiogenesis, promoting the normalization of tumor blood vessels (56, 57).